Elena Castro, Consultant Medical Oncologist at Hospital Universitario 12 Octubre, shared on LinkedIn:
“As an ESMO Ambassador, I have carefully reviewed the programme and identified the most interesting track: prostate cancer, of course.
Here are the links to the ESMO2026 prostate cancer sessions:
Friday 23rd:
- Rapid oral session.
- Posters session.
- Special Symposium: Emerging therapeutic strategies in advanced prostate cancer.
Saturday 24th:
- Proffered paper session.
- Presidential Symposium 1: LBA4 – Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801). Presented by Dr Tamim Niazi, Discussed by Dr Silke Gillessen
Sunday 25th:
Keynote lecture, From diagnosis to destruction: The power of radioligand therapeutics in cancer treatment. Presented by Dr Ken Herrmann
Monday 26th:
Educational session: How to optimise care for patients receiving prostate cancer systemic therapy
Challenge your expert session: Challenges in the management of neuro-endocrine and small cell prostate cancer
Expert: Dr Himisa Beltran, Chair: Dr Ravindran Kanesvaran
Tuesday 27th:
Scientific Congress Highlights, Dr. Christopher Sweeney.”
This also can be interesting:
10 Prostate Cancer Trials to Watch at ESMO 2026
